PFE

Pfizer, Inc.

52.43
USD
2.93%
52.43
USD
2.93%
38.93 61.71
52 weeks
52 weeks

Mkt Cap 292.46B

Shares Out 5.58B

Chat
Send me real-time posts from this site at my email

Biohaven's drug for genetic neurological disease fails late-stage study

May 23 (Reuters) - Biohaven Pharmaceutical BHVN.N said on Monday a late-stage trial of its drug against spinocerebellar ataxia, a genetic neurological disease, failed to meet the main goal of the study. Spinocerebellar ataxia is a progressive disorder that causes symptoms such as uncoordinated movement, difficulties swallowing and muscle wasting. Biohaven said patients in both the drug and the placebo groups showed less-than-expected change in disease progression, which led to the study not meeting statistical significance. Pfizer Inc PFE.N earlier this month said it would buy Biohaven in a $11.6 billion deal in a bet on the company's commercial migraine drug and other drugs in development. (Reporting by Leroy Leo and Amruta Khandekar in Bengaluru; Editing by Aditya Soni) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue